Panacea Biotec マネジメント

マネジメント基準チェック /34

Panacea Biotecの CEO はRajesh Jainで、 Feb2002年に任命され、の在任期間は 22.75年です。の年間総報酬は₹ 9.01Mで、 66.6%給与と33.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の49.33%を直接所有しており、その価値は₹ 12.88B 。経営陣と取締役会の平均在任期間はそれぞれ9.5年と8.6年です。

主要情報

Rajesh Jain

最高経営責任者

₹9.0m

報酬総額

CEO給与比率	66.6%
CEO在任期間	22.8yrs
CEOの所有権	49.3%
経営陣の平均在職期間	9.5yrs
取締役会の平均在任期間	8.6yrs

経営陣の近況

Recent updates

CEO報酬分析

Panacea Biotec の収益と比較して、Rajesh Jain の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-₹147m
Jun 30 2024	n/a	n/a	-₹279m
Mar 31 2024	₹9m	₹6m	-₹12m
Dec 31 2023	n/a	n/a	-₹117m
Sep 30 2023	n/a	n/a	₹99m
Jun 30 2023	n/a	n/a	₹334m
Mar 31 2023	₹8m	₹6m	-₹332m
Dec 31 2022	n/a	n/a	₹12b
Sep 30 2022	n/a	n/a	₹11b
Jun 30 2022	n/a	n/a	₹11b
Mar 31 2022	₹8m	₹6m	₹11b
Dec 31 2021	n/a	n/a	-₹2b
Sep 30 2021	n/a	n/a	-₹2b
Jun 30 2021	n/a	n/a	-₹2b
Mar 31 2021	₹7m	₹6m	-₹1b
Dec 31 2020	n/a	n/a	-₹2b
Sep 30 2020	n/a	n/a	-₹1b
Jun 30 2020	n/a	n/a	-₹2b
Mar 31 2020	₹8m	₹6m	-₹2b
Dec 31 2019	n/a	n/a	₹653m
Sep 30 2019	n/a	n/a	₹715m
Jun 30 2019	n/a	n/a	₹482m
Mar 31 2019	₹7m	₹6m	₹410m
Mar 31 2018	₹7m	₹6m	-₹716m

報酬と市場: Rajeshの総報酬 ($USD 106.91K ) は、 Indian市場 ($USD 271.25K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Rajeshの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Rajesh Jain (60 yo)

22.8yrs

在職期間

₹9,010,000

報酬

Dr. Rajesh Jain, Ph D has been Managing Director at Panacea Biotec Limited since March 12, 2018 and serves as its Whole-Time Director and serves as its Chairman of the Board at Panacea Biotec Limited since...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Rajesh Jain	Chairman of the Board & MD	22.8yrs	₹9.01m	49.33% ₹ 12.9b
Sandeep Jain	Joint MD & Executive Director	22.8yrs	₹8.37m	15.45% ₹ 4.0b
Devender Gupta	CFO & Head of Information Technology	9.5yrs	₹6.43m	データなし
Khalid Syed	Chief Scientific Officer	no data	₹6.53m	データなし
Vinod Goel	Group CFO	9.5yrs	₹8.43m	データなし
Ankesh Jain	Whole-Time Director	less than a year	₹3.03m	データなし
Rajeeva Mangalum	Chief Operating Officer	5yrs	データなし	データなし
Naresh Gupta	General Manager of Accounts & Taxation	no data	データなし	データなし
Ashish Jain	Chief Information Officer	no data	データなし	0.00082% ₹ 214.1k
Gurinder Singh	Senior Vice President of Sales	no data	₹5.61m	データなし
Kulvinder Sarao	Senior Vice President of Human Resources	no data	₹6.10m	データなし
Dinesh Singla	Senior Vice President of Pharma Research & Pharma Regulatory Affairs	5yrs	データなし	データなし

9.5yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: 531349の経営陣は経験豊富で経験豊富です（平均在職期間は9.5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Rajesh Jain	Chairman of the Board & MD	40yrs	₹9.01m	49.33% ₹ 12.9b
Sandeep Jain	Joint MD & Executive Director	40yrs	₹8.37m	15.45% ₹ 4.0b
Ankesh Jain	Whole-Time Director	8.6yrs	₹3.03m	データなし
Narotam Juneja	Additional Non-Executive Non-Independent Director	2.6yrs	₹22.00k	データなし
Manjula Upadhyay	Non-Executive Independent Director	9.7yrs	₹20.00k	データなし
Mukul Gupta	Non-Executive Independent Director	8.6yrs	₹20.00k	データなし
Ambika Sharma	Non-Executive Independent Director	less than a year	データなし	データなし

8.6yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: 531349の取締役会は経験豊富であると考えられます ( 8.6年の平均在任期間)。

Panacea Biotec マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Joint MD & Executive Director recently sold ₹29m worth of stock

Panacea Biotec Limited Announces Demise of Bhupinder Singh, Independent Director, Member of the Board and Committee

Joint MD & Executive Director recently sold ₹1.3m worth of stock

Panacea Biotec Limited, Annual General Meeting, Sep 27, 2024

Joint MD & Executive Director recently sold ₹1.3m worth of stock

Insufficient new directors

Recent updates

Joint MD & Executive Director recently sold ₹29m worth of stock

Second quarter 2025 earnings released: EPS: ₹0.77 (vs ₹1.35 loss in 2Q 2024)

Panacea Biotec Limited to Report Q2, 2025 Results on Nov 13, 2024

Panacea Biotec Limited Announces Demise of Bhupinder Singh, Independent Director, Member of the Board and Committee

Joint MD & Executive Director recently sold ₹1.3m worth of stock

New minor risk - Share price stability

First quarter 2025 earnings released: ₹2.59 loss per share (vs ₹1.79 profit in 1Q 2024)

Panacea Biotec Limited, Annual General Meeting, Sep 27, 2024

Panacea Biotec Limited to Report Q1, 2025 Results on Aug 14, 2024

Joint MD & Executive Director recently sold ₹1.3m worth of stock

Full year 2024 earnings released: ₹0.19 loss per share (vs ₹5.43 loss in FY 2023)

New minor risk - Market cap size

New minor risk - Market cap size

Third quarter 2024 earnings released: ₹0.37 loss per share (vs ₹3.16 profit in 3Q 2023)

Panacea Biotec Limited to Report Q3, 2024 Results on Feb 13, 2024

Panacea Biotec Launches EasyFourPol® in India and Receives Registration of Valganciclovir Powder for Oral Solution in Germany

Second quarter 2024 earnings released: ₹1.35 loss per share (vs ₹2.56 profit in 2Q 2023)

Panacea Biotec Limited to Report Q2, 2024 Results on Nov 10, 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

First quarter 2024 earnings released: EPS: ₹1.79 (vs ₹9.17 loss in 1Q 2023)

Panacea Biotec Limited to Report Q1, 2024 Results on Aug 12, 2023

Full year 2023 earnings released: ₹5.51 loss per share (vs ₹176 profit in FY 2022)

Third quarter 2023 earnings released: EPS: ₹3.16 (vs ₹8.03 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹2.56 (vs ₹8.65 loss in 2Q 2022)

Insufficient new directors

Panacea Biotec Limited Announces Demise of Shri Soshil Kumar Jain, the Founder, Chairman

Panacea Biotec Limited to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: ₹9.17 loss per share (vs ₹9.36 loss in 1Q 2022)

Panacea Biotec Limited, Annual General Meeting, Sep 28, 2022

Panacea Biotec Limited to Report Q1, 2023 Results on Aug 09, 2022

Insufficient new directors

Full year 2022 earnings released: EPS: ₹176 (vs ₹23.88 loss in FY 2021)

Insufficient new directors

Panacea Biotec Limited Appoints Narotam Kumar Juneja as an Additional Director

Insufficient new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

First quarter 2022 earnings released: ₹9.36 loss per share (vs ₹5.41 loss in 1Q 2021)

Panacea Biotec Announces Receipt of Manufacturing License to Produce Sputnik V Vaccine at Baddi, Himachal Pradesh

Full year 2021 earnings released: ₹23.87 loss per share (vs ₹30.67 loss in FY 2020)

The Russian Direct Investment Fund and Panacea Biotec Announce the Launch of Production of the Russian Sputnik V Vaccine Against Coronavirus

New 90-day low: ₹185

Third quarter 2021 earnings released: ₹6.54 loss per share (vs ₹3.29 loss in 3Q 2020)

Panacea Biotec Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹246

Second quarter 2021 earnings released: ₹3.09 loss per share

Panacea Biotec Limited, Annual General Meeting, Dec 24, 2020

New 90-day low: ₹181

Panacea Biotec Limited Announces Resignation of Sunanda Jain and Mr. Sumit Jain, Whole-Time Directors

Panacea Biotec Limited (BSE:531349) completed the spin-off of Radhika Heights Limited.

Panacea Biotec Limited Announces Completion of its Phase I/II Study to Evaluate the Safety and Immunogenicity of Vaccine, DengiAll, Single-Dose Live-Attenuated Tetravalent Vaccine

First quarter earnings released

First quarter earnings released

Panacea Biotec Limited to Report Q1, 2021 Results on Sep 03, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34